“…24,25 Historically, the enzymatic inactivation of beta-lactam antibiotics has been well-studied, 26,27,28 and strategies aimed at combatting this resistance using an adjuvant approach-where the antibiotic is co-administered with a small molecule inhibitor of the inactivating enzyme-have emerged as fundamentally useful tools for the rescue of betalactam antibiotics in the clinic. 29,30,31,32 With the discovery and characterization of 10 tetracycline-inactivating enzymes with varying resistance profiles, 33,34 the development of small molecule inhibitors of tetracycline destructase enzymes stands at the forefront of strategies aimed at combatting the imminent clinical emergence of this resistance mechanism in multi-drug resistant infections. We herein report preliminary findings focused on understanding the factors that influence inhibitor potency and stability en route to the development of viable adjuvant approaches to counter tetracycline resistance by enzymatic inactivation.…”